Serum Level of Fibroblast Growth Factor 21 in Type 2 Diabetic Patients with and without Metabolic Syndrome

Abstract

Effect of FGF21 on metabolic syndrome patients is not exactly clear. In the present study, we assessed serum level of fibroblast growth factor 21 in type 2 diabetic patients with and without metabolic syndrome in Gorgan. The study groups consisted of 120 patients with type 2 diabetes and 60 healthy subjects. Diabetic patients divided into two groups. All subjects were matched according to age and sex. The mean waist circumference, systolic and diastolic blood pressure, triglyceride and fasting blood glucose levels and body mass index were significantly higher in the subjects with metabolic syndrome than control group, but the mean HDL-cholesterol was significantly lower (p = 0.0001). Mean serum level of FGF21 was higher in type 2 diabetic subjects with and without metabolic syndrome than that of control subject (p = 0.0001). There were significant negative correlation between FGF21 and BMI, diastolic blood pressure and HDL-cholesterol in subjects with metabolic syndrome (p<0.05). There were also significant negative correlation between FGF21 and cholesterol and HDL-cholesterol in control group (p<0.05). The findings of this study suggest that serum FGF21 are higher in patients with type 2 diabetes with and without metabolic syndrome than in age and sex matched control group. Our study shows that some of metabolic syndrome components (especially HDL-cholesterol) are associated with high serum FGF21 levels. Because of different effects of FGF21 in rodents, primates and in humans, it may require more investigating on metabolic effects of FGF21 in human's samples.

Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus and Type 2 Diabetes Mellitus

“…According to the results of the present research, serum FGF21 concentration was significantly higher in 2DM as compared with nondiabetic individuals (control group 1). This is consistent with numerous reports in which FGF21 levels were also observed to be higher in type 2 diabetic patients than in subjects free from diabetes [ 16 , 17 ]. Additionally, some papers indicate the potential role of FGF21 as an early predictor of type 2 diabetes development [ 18 ].…”

“…The present results also indicated that the serum levels of FGF21 were positively correlated with the concentration of blood glucose in GDM patients. We have not observed this relationship in 2DM, what is consistent with the study by Shafaei et al [ 16 ], but it is not consistent with another report, where FGF21 and glucose were significantly correlated [ 23 ]. This inconsistency is probably due to the fact that the studied group was patients with newly diagnosed 2DM while our patients have been diagnosed with diabetes more than 5 years.…”

Increased serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-analysis

“…The basic characteristics of included studies are further summarised in detail in Table 1. [18][19][20][21][22][23][24][25][26][27][28] FGF-21 concentration was compared between patients with T2DM and age-, sex-and BMI-matched healthy controls in each included study. Quality assessment by NOS was determined among each included studies (online supplementary table 1) (table 1).…”

Epigenetic scores for the circulating proteome as tools for disease prediction

“…For example, the FGF-21 proxy measure associated with incident stroke and diabetes. Serum and plasma measures of FGF-21 have been shown to be predictive of type 2 diabetes and metabolic syndrome [30][31][32][33][34][35] , with FGF-21 implicated in the response to metformin 36 . FGF-21 has also been characterised as a blood-based marker for poor cardiovascular health, both generally and in those with type 2 diabetes [37][38][39][40] .…”